Drug Approval | February 16, 2023
Zydus receives tentative approval from the USFDA for Canagliflozin tablets
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
The findings support the fact that further extension of nationwide cardiovascular disease (CVD) risk identification programs and prevention strategies to reduce the occurrence of cardiovascular diseases are warranted
Subscribe To Our Newsletter & Stay Updated
